EGFR and non-small cell lung carcinoma: This LB CGP test was originally approved for the identification of EGFR mutations in patients with non-small cell lung cancer (NSCLC), in particular deletions in exon 19, L858R in exon 21, or T790M in exon 20, to predict the benefit from osimertinib.